21. June 2006. For most people, the day was like all other days is not very important. But for the overweight people in the United Kingdom, the day is always in mind. For the day, Acomplia, the drug for obesity wonder was sold on prescription. Search for Acomplia pill system has been for years. And all eyes have been if the drug is a miracle. After Fen-Phen, Acomplia pill regime was due to excessive drug use and many people have had confidence in the drug, giving them the freedom of excess fat. Therefore, for the approval of Acomplia is like rain in a desert. It is the hope of finally getting rid of fats, which not only looks awkward, but also susceptible to many diseases of the heart. Acomplia is the brand name of Rimonabant. French pharmaceutical group Sanofi-Synthelabo, could easily sense the great market for these drugs. In the United Kingdom, 46% of men and 32% of women are overweight, for example, a body mass index of 25-30 kg / m 2 In addition, 17% of men and 21% women are obese , ie with a body mass index over 30 kg / m 2 in the U.S. and Europe for 100 million people are overweight. This gives the market the pill Acomplia regime a huge one. All agencies, Acomplia for sale on prescription, being swamped with messages such as orders for authorization in the United Kingdom. It is said that if the root of the problem is the best way to solve the problem. Acomplia pill regime is the same. It aims to certain receptors in our brain, the feeling of pleasure of eating. These are the cannabinoid receptors. It is these receptors, tickled, if you consume cannabis. This is why we are hungry, after smoking a joint of marijuana. Blocks cannabinoid receptors wetting aid appetite. Therefore, the weight loss. With the slimming pill Acomplia diet is significant. In a placebo-controlled study on 6800 patients with Acomplia (with diet and physical activity), or the average rate of reduction of weight, not less than 6.5 kg, 1.6 kg compared to placebo, or almost four times much as the placebo. Rimonabant is the confirmation by the FDA in the United States. Sanofi plans "rimonabant" under the new name "Zimulti" here. Until then, the Americans hear about the FDA approval, which should continue with destiny. And if die-hard fan of the drug when they can not, however, the visit of a doctor in the United Kingdom and the purchase of a local pharmacy Acomplia here. The pain is probably irrelevant to the pain of obesity.